{"title": "Uso compasivo de dupilumab para pacientes adultos con penfigoide ampolloso", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT05906706", "hostname": "ichgcp.net", "description": "El objetivo del programa es proporcionar a los pacientes con penfigoide ampollar (BP), que participaron en el estudio de fase 2/3 R668-BP-1902 (NCT04206553), tr.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2023-06-07", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Uso compasivo de dupilumab para pacientes adultos con penfigoide ampolloso\n7 de junio de 2023 actualizado por:\n[Regeneron Pharmaceuticals](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Regeneron%20Pharmaceuticals)\nUn programa abierto de acceso ampliado de dupilumab en pacientes adultos con penfigoide ampolloso\nEl objetivo del programa es proporcionar a los pacientes con penfigoide ampollar (BP), que participaron en el estudio de fase 2/3 R668-BP-1902 (NCT04206553), tratamiento con dupilumab y evaluar la seguridad a largo plazo de dupilumab.\nDescripci\u00f3n general del estudio\nEstado\nTemporalmente no disponible\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nLas solicitudes de acceso ampliado solo se consideran en respuesta a solicitudes de poblaci\u00f3n de pacientes de tama\u00f1o intermedio. La disponibilidad depender\u00e1 de la ubicaci\u00f3n.\nTipo de estudio\nAcceso ampliado\nTipo de acceso ampliado\n- Poblaci\u00f3n de tama\u00f1o intermedio\nCriterios de participaci\u00f3n\nLos investigadores buscan personas que se ajusten a una determinada descripci\u00f3n, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.\nCriterio de elegibilidad\nEdades elegibles para estudiar\n- Adulto\n- Adulto Mayor\nAcepta Voluntarios Saludables\nN/A\nDescripci\u00f3n\nCriterios clave de inclusi\u00f3n:\n1. Finalizaci\u00f3n de la visita de finalizaci\u00f3n del estudio (EOS) en el estudio principal de fase 2/3 de dupilumab, R668-BP-1902 (NCT04206553)\nCriterios clave de exclusi\u00f3n:\n- Pacientes que, durante el estudio original de dupilumab, R668-BP-1902 (NCT04206553), desarrollaron un evento adverso grave (SAE) y/o un evento adverso (AE) considerado relacionado con el f\u00e1rmaco del programa y que condujo a la interrupci\u00f3n del producto en investigaci\u00f3n\n- Tratamiento con f\u00e1rmacos inmunosupresores/inmunomoduladores no esteroideos (p. ej., micofenolato mofetilo, azatioprina o metotrexato) en las 4 semanas anteriores a la visita inicial\n- Tratamiento con productos biol\u00f3gicos dirigidos a BP, como se define en el protocolo\n- Tratamiento con una vacuna viva (atenuada) dentro de las 4 semanas anteriores a la visita inicial\n- Uso planificado o anticipado de cualquier medicamento o procedimiento prohibido durante el tratamiento del programa\n- Enfermedad(es) grave(s) concomitante(s) que, a juicio del m\u00e9dico tratante, afectar\u00edan adversamente la participaci\u00f3n del paciente en el programa\nNOTA: Se aplican otros criterios de inclusi\u00f3n/exclusi\u00f3n definidos en el protocolo\nPlan de estudios\nEsta secci\u00f3n proporciona detalles del plan de estudio, incluido c\u00f3mo est\u00e1 dise\u00f1ado el estudio y qu\u00e9 mide el estudio.\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nColaboradores e Investigadores\nAqu\u00ed es donde encontrar\u00e1 personas y organizaciones involucradas en este estudio.\nPatrocinador\nColaboradores\nFechas de registro del estudio\nEstas fechas rastrean el progreso del registro del estudio y los env\u00edos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los est\u00e1ndares de control de calidad espec\u00edficos antes de publicarlos en el sitio web p\u00fablico.\nFechas de registro del estudio\nEnviado por primera vez\n7 de junio de 2023\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\n7 de junio de 2023\nPublicado por primera vez (Estimado)\n16 de junio de 2023\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Estimado)\n16 de junio de 2023\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n7 de junio de 2023\n\u00daltima verificaci\u00f3n\n1 de mayo de 2023\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- R668-BP-2290-EAP\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Penfigoide ampolloso\n-\nNCT05984381A\u00fan no reclutando\n-\nNCT05954416ReclutamientoNeurofibromatosis tipo 1 | Ictiosis | Displasia ectod\u00e9rmica | Albinismo | P\u00e9nfigo | Penfigoide de la membrana mucosa | Epiderm\u00f3lisis ampollosa hereditaria | Queratodermia palmoplantar | Incontinencia pigmentaria\n-\nNCT05681481Reclutamiento\n-\nNCT05649579ReclutamientoPenfigoide ampolloso\n-\nNCT05594472ReclutamientoPenfigoide ampolloso | Pemphigus vulgaris\n-\nNCT05366127A\u00fan no reclutando\n-\nNCT05284929Reclutamiento\n[Frecuencias de alelos y haplotipos del ant\u00edgeno leucocitario humano clase II (DRB1 y DQB1) en pacientes con p\u00e9nfigo vulgar entre la poblaci\u00f3n rusa](https://ichgcp.net/es/clinical-trials-registry/NCT05284929)Penfigoide ampolloso | S\u00edndrome de Stevens-Johnson | Necrolisis Epid\u00e9rmica T\u00f3xica | P\u00e9nfigo\n-\nNCT05267600Reclutamiento\n-\nNCT04612790Reclutamiento\n-\nNCT04465292A\u00fan no reclutandoPenfigoide Ampolloso\nEnsayos cl\u00ednicos sobre dupilumab\n-\nNCT06012448A\u00fan no reclutando\n[Los efectos inmunol\u00f3gicos de dupilumab en el tratamiento de la reacci\u00f3n de hipersensibilidad d\u00e9rmica](https://ichgcp.net/es/clinical-trials-registry/NCT06012448)Reacci\u00f3n de hipersensibilidad d\u00e9rmica\n-\nNCT06004986ReclutamientoDermatitis at\u00f3pica | Dermatitis at\u00f3pica Eccema\n-\nNCT05991323A\u00fan no reclutando\n-\nNCT05983068A\u00fan no reclutando\n-\nNCT05967884A\u00fan no reclutandoC\u00e1ncer de mama\n-\nNCT05964465ReclutamientoRinosinusitis cr\u00f3nica con p\u00f3lipos nasales\n-\nNCT05942222Reclutamiento\n[Un estudio comparativo aleatorizado y real de dupilumab versus mepolizumab en pacientes daneses con CRSwNP (TORNADO)](https://ichgcp.net/es/clinical-trials-registry/NCT05942222)Eosinofilia | Rinosinusitis cr\u00f3nica con p\u00f3lipos nasales | Asma; eosinof\u00edlico\n-\nNCT05938972ReclutamientoRinosinusitis cr\u00f3nica con p\u00f3lipos nasales\n-\nNCT05932654Reclutamiento\n-\nNCT05878093ReclutamientoRinosinusitis cr\u00f3nica con p\u00f3lipos nasales", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT05906706", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT05906706&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT05906706", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Regeneron%20Pharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bullous%20Pemphigoid", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=dupilumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Regeneron%20Pharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Sanofi", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Immune%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Autoimmune%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Skin%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Inflammatory%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Skin%20Diseases%2C%20Vesiculobullous", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pemphigoid%2C%20Bullous", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT05984381", "https://ichgcp.net/es/clinical-trials-registry/NCT05954416", "https://ichgcp.net/es/clinical-trials-registry/NCT05681481", "https://ichgcp.net/es/clinical-trials-registry/NCT05649579", "https://ichgcp.net/es/clinical-trials-registry/NCT05594472", "https://ichgcp.net/es/clinical-trials-registry/NCT05366127", "https://ichgcp.net/es/clinical-trials-registry/NCT05284929", "https://ichgcp.net/es/clinical-trials-registry/NCT05267600", "https://ichgcp.net/es/clinical-trials-registry/NCT04612790", "https://ichgcp.net/es/clinical-trials-registry/NCT04465292", "https://ichgcp.net/es/clinical-trials-registry/NCT06012448", "https://ichgcp.net/es/clinical-trials-registry/NCT06004986", "https://ichgcp.net/es/clinical-trials-registry/NCT05991323", "https://ichgcp.net/es/clinical-trials-registry/NCT05983068", "https://ichgcp.net/es/clinical-trials-registry/NCT05967884", "https://ichgcp.net/es/clinical-trials-registry/NCT05964465", "https://ichgcp.net/es/clinical-trials-registry/NCT05942222", "https://ichgcp.net/es/clinical-trials-registry/NCT05938972", "https://ichgcp.net/es/clinical-trials-registry/NCT05932654", "https://ichgcp.net/es/clinical-trials-registry/NCT05878093", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/argentina", "https://ichgcp.net/es/cro-list/country/cambodia", "https://ichgcp.net/es/cro-list/country/congo", "https://ichgcp.net/es/cro-list/country/finland", "https://ichgcp.net/es/cro-list/country/kosovo", "https://ichgcp.net/es/cro-list/country/mali", "https://ichgcp.net/es/cro-list/country/mozambique", "https://ichgcp.net/es/cro-list/country/myanmar", "https://ichgcp.net/es/cro-list/country/philippines", "https://ichgcp.net/es/cro-list/country/south_korea", "https://ichgcp.net/es/cro-list/country/sri_lanka", "https://ichgcp.net/es/cro-list/country/tunisia", "https://ichgcp.net/es/cro-list/country/uzbekistan", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/tunisia/company/keyrus_life_science", "https://ichgcp.net/es/cro-list/country/tunisia/company/clinica_group", "https://ichgcp.net/es/cro-list/country/tunisia/company/sgs", "https://ichgcp.net/es/cro-list/country/tunisia/company/across_global", "https://ichgcp.net/es/cro-list/country/tunisia/company/nagy_research", "https://ichgcp.net/es/cro-list/country/tunisia/company/mct", "https://ichgcp.net/es/cro-list/country/tunisia/company/mesned_cro", "https://ichgcp.net/es/cro-list/country/tunisia", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT05906706", "https://ichgcp.net/de/clinical-trials-registry/NCT05906706", "https://ichgcp.net/clinical-trials-registry/NCT05906706", "https://ichgcp.net/es/clinical-trials-registry/NCT05906706", "https://ichgcp.net/fr/clinical-trials-registry/NCT05906706", "https://ichgcp.net/it/clinical-trials-registry/NCT05906706", "https://ichgcp.net/hu/clinical-trials-registry/NCT05906706", "https://ichgcp.net/nl/clinical-trials-registry/NCT05906706", "https://ichgcp.net/no/clinical-trials-registry/NCT05906706", "https://ichgcp.net/pl/clinical-trials-registry/NCT05906706", "https://ichgcp.net/pt/clinical-trials-registry/NCT05906706", "https://ichgcp.net/fi/clinical-trials-registry/NCT05906706", "https://ichgcp.net/sv/clinical-trials-registry/NCT05906706", "https://ichgcp.net/cs/clinical-trials-registry/NCT05906706", "https://ichgcp.net/ru/clinical-trials-registry/NCT05906706", "https://ichgcp.net/ja/clinical-trials-registry/NCT05906706", "https://ichgcp.net/zh/clinical-trials-registry/NCT05906706", "https://ichgcp.net/ko/clinical-trials-registry/NCT05906706", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}